Date: 2015-06-30
Type of information: Collaboration agreement
Compound: Clevegen®
Company: Faron Pharmaceuticals (Finland) the Turku PET Center (Finland)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration R&D
Action mechanism: monoclonal antibody. Clevegen® is an antibody designed to prevent tumour growth and metastasis which targets the tumour immune suppressor molecule, Clever-1. Clever-1 is an adhesion, scavenging and signaling molecule involved in cancer growth and is found in lymphatic and vascular endothelium as well as type 2 immunosuppressive macrophages.
Disease:
Details: * On June 30,2015, Faron Pharmaceuticals announced a collaboration with the Turku PET Center, one of the largest centers in Europe, on the development of its novel cancer immunotherapy Clevegen®. Clevegen® targets a proprietary cell surface receptor called Clever-1. A research grant from Tekes, the Finnish Technology and Development Center, will support the funding of the project. The PET (positron emission tomography) project will assist Faron in the design of an optimal use of Clevegen® for cancer treatment, as well as guide diagnosis, pre-clinical and clinical development and measure potentially novel clinical end points to demonstrate efficacy.
Financial terms:
Latest news:
